sodium fusidate
Phase 2- Indications
- Melioidosis, Cystic fibrosis infections
Company intelligence / Profile preview
Arrevus
Durham, North Carolina, United Statesdnb.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 2
01
Overview
Arrevus has a Phase III clinical program (ARV-1801) targeting cystic fibrosis pulmonary exacerbations. Their lead DPC, ARV-1502, has successfully completed animal activity testing and has an issued US composition of matter patent[1][4].
- Therapeutic areas
- PulmonologyRare DiseasesInfectious Diseases
- Modalities
- Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Arrevus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arrevus.